Theratechnologies Inc. (TSE:TH) had its target price cut by analysts at National Bank Financial from C$9.75 to C$8.75 in a research report issued on Tuesday. The brokerage presently has an “outperform” rating on the stock. National Bank Financial’s price objective points to a potential upside of 19.37% from the company’s current price.

Separately, Scotiabank cut their target price on Theratechnologies from C$9.50 to C$9.25 and set an “outperform” rating on the stock in a report on Friday, September 29th.

Shares of Theratechnologies (TSE TH) traded down C$0.17 on Tuesday, hitting C$7.33. The company had a trading volume of 78,814 shares, compared to its average volume of 152,934. Theratechnologies has a 12 month low of C$2.61 and a 12 month high of C$8.72.

ILLEGAL ACTIVITY WARNING: “Theratechnologies Inc. (TH) Price Target Lowered to C$8.75 at National Bank Financial” was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/theratechnologies-inc-th-price-target-lowered-to-c8-75-at-national-bank-financial/1703027.html.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

Receive News & Ratings for Theratechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.